AZN predicted sales would reach 45B by 2023 when they rejected PFE's bid in 2013. They pretty much hit that goal one year early. Hindsight is 20/20, and I am not sure the buyout would have gone through anyway, but this was one that got away. PFE undervalued AZN's oncology pipeline at the time
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.